Research Webinar Series: Reprogramming The Immune System to Halt Myasthenia Gravis

Reprogramming The Immune System to Halt Myasthenia Gravis: Introduction to the COUR Nanoparticle Technology and Trial in MG.
At COUR, Dr. Paul Peloso, chief medical officer, is leading the development of a novel, groundbreaking technology that could reprogram the immune system and transform the treatment of myasthenia gravis (MG). COUR nanotechnology allows reprogramming of the immune system away from the destructive inflammatory response towards a more normal, housekeeping status. By infusing negatively charged nanoparticles that are packaged with portions of the antibodies that drive the negative effects in MG, that being the anti-ACH antibody, the immune system can be trained to reduce its destructive profile. Dr. Peloso's presentation will highlight the COUR technology and introduce the early clinical trial in generalized MG, offering new hope for more effective treatments and improved outcomes for patients.